Lansforsakringar Fondforvaltning AB publ Acquires Shares of 13,541 United Therapeutics Co. (NASDAQ:UTHR)

Lansforsakringar Fondforvaltning AB publ acquired a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,541 shares of the biotechnology company's stock, valued at approximately $4,778,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Signaturefd LLC lifted its holdings in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after buying an additional 30 shares in the last quarter. Parallel Advisors LLC grew its position in United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 30 shares during the last quarter. Anchor Investment Management LLC grew its position in United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the last quarter. Great Lakes Advisors LLC grew its position in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after purchasing an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after purchasing an additional 33 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $316.07, for a total value of $3,476,770.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at approximately $11,625,370.67. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,500 shares of company stock worth $16,923,950. 10.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley increased their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $4.03 on Friday, reaching $316.34. The company's stock had a trading volume of 886,326 shares, compared to its average volume of 443,403. United Therapeutics Co. has a 1-year low of $266.98 and a 1-year high of $417.82. The firm has a market cap of $14.27 billion, a PE ratio of 13.89, a PEG ratio of 0.97 and a beta of 0.58. The business's 50-day moving average price is $299.49 and its two-hundred day moving average price is $335.31.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.17 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.